Fortitude Family Office’s Denali Therapeutics DNLI Stock Holding History

Fortitude Family Office’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57K	Buy	61 +26	+74%	+$534	﹤0.01%	1584
2026 Q1	$672	Buy	35 +28	+400%	+$557	﹤0.01%	1619
2025 Q4	$116	Sell	7 -2	-22%	-$34	﹤0.01%	1887
2025 Q3	$131	Sell	9 -32	-78%	-$460	﹤0.01%	1946
2025 Q2	$574	Buy	+41	New	+$577	﹤0.01%	1728

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortitude Family Office's DNLI Position: Q2 2026 in Review

Fortitude Family Office increased its Denali Therapeutics (DNLI) stake by 74% in Q2 2026, buying an estimated $534 and bringing the position to 61 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1584.

Fortitude Family Office first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Fortitude Family Office held 61 shares of Denali Therapeutics worth $1.57K as of Q2 2026.
Fortitude Family Office bought 26 Denali Therapeutics shares in Q2 2026, an estimated $534.
Denali Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1584 holding.
Fortitude Family Office first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.